This is Vicore
Our story
Our ambition and strategic priorities
Collaborations and partnerships
Scientific advisors
Management team
Board of Directors
Science
Scientific rationale
ATRAG MoA in IPF
Intellectual property and orphan drug designation
Publications
Key publications
Posters
Our programs
Pipeline
ASPIRE Ph2b trial
Rare lung diseases
Buloxibutid (C21) – IPF
Almee – PF anxiety
Buloxibutid (C21) – PAH
Future ATRAG indications
Our drug discovery engine
Almee™
Career
Our collaborative business model
Meet the Team
Open positions
Contact
Media
Press releases (ENG)
Pressmeddelanden (SVE)
Image bank
Investors
Investors
Overview
Press releases
Rights Issue, September 2024
The share
Financial reports
Financial calendar
Events & Presentations
Corporate governance
Image bank
Investor Relations contact
Investerare (SE)
Översikt
Pressmeddelanden
Företrädesemission September 2024
Aktien
Finansiella rapporter
Finansiell kalender
Events & Presentationer
Bolagsstyrning
Bolagsstämma
Bildbank
Investerarkontakt
Patients and caregivers
IPF
Background
Patient stories
Patient advocacy organizations
Transparency
Access policy
This is Vicore
Our story
Our ambition and strategic priorities
Collaborations and partnerships
Scientific advisors
Management team
Board of Directors
Science
Scientific rationale
ATRAG MoA in IPF
Intellectual property and orphan drug designation
Publications
Key publications
Posters
Our programs
Pipeline
ASPIRE Ph2b trial
Rare lung diseases
Buloxibutid (C21) – IPF
Almee – PF anxiety
Buloxibutid (C21) – PAH
Future ATRAG indications
Our drug discovery engine
Almee™
Career
Our collaborative business model
Meet the Team
Open positions
Contact
Media
Press releases (ENG)
Pressmeddelanden (SVE)
Image bank
Investors
Investors
Overview
Press releases
Rights Issue, September 2024
The share
Financial reports
Financial calendar
Events & Presentations
Corporate governance
Image bank
Investor Relations contact
Investerare (SE)
Översikt
Pressmeddelanden
Företrädesemission September 2024
Aktien
Finansiella rapporter
Finansiell kalender
Events & Presentationer
Bolagsstyrning
Bolagsstämma
Bildbank
Investerarkontakt
Patients and caregivers
IPF
Background
Patient stories
Patient advocacy organizations
Transparency
Access policy
Home
/
Investerare (SE)
/
Bolagsstyrning
/
Intern kontroll
Översikt
Pressmeddelanden
Företrädesemission September 2024
Aktien
Aktien
Aktieägare
Ägande styrelse och ledning
Aktiekapitalets utveckling
Emissioner
Analytiker
Listningsprospekt
Finansiella rapporter
Finansiell kalender
Events & Presentationer
Bolagsstyrning
Bolagsstyrningsrapporter
Bolagsstämma
Valberedning
Styrelsen
Revisionsutskott
Ersättningsutskott
Vetenskapligt utskott
Ledning
Arvoden och ersättningar
Revisorer
Bolagsordning
Bildbank
Prenumerera på nyheter
Investerarkontakt